Most patients with acute myeloid leukemia (AML) relapse and die with chemotherapy resistant disease. With 7,000 deaths per year in the U.S. due to AML, novel agents which kill multi-drug resistant blasts are needed. Our laboratory has focused on the treatment of such patients with diphtheria fusion proteins. These molecules consist of the catalytic and translocation domains of diphtheria toxin (DT388) fused to leukemic blast selective ligands. We initially prepared DT388GMCSF by linking DT388 to human granulocyte-macrophage colony stimulating factor (GMCSF). In an ongoing clinical trial in refractory AML patients, remissions have been observed. However, side effects related to DT388GMCSF binding and inducing cytokine release from patient monocytes have occurred, necessitating steroid and antibiotic prophylaxis. Further, some patients failed to show leukemic cytoreductions. To improve the effectiveness and reduce toxicity, we synthesized a second generation fusion protein, DT388IL3, consisting of DT388 fused to human interleukin-3 (IL3). The new fusion protein does not bind monocytes nor induce secretion of cytokines. Remarkably, DT3881L3 binds and intoxicates leukemic progenitors from all types of myeloid leukemias. DT388IL3 is currently being manufactured under GMP at Wake Forest University. In this grant application, we request funding to complete the preclinical and preliminary clinical evaluation of DT388IL3.
In Specific Aim 1, anti-leukemic efficacy will be tested in leukemic SCID mice.
Specific Aim 2 will study safety in non-human primates bearing cross-reactive receptors. Results from these experiments will facilitate the submission of an INDA.
Specific Aim 3 will determine the safe dose, dose-limiting toxicities, cytokine secretion, pharmacokinetics, and immune response and correlate toxicities with cytokine, DT388IL3 and anti-DT388IL3 blood levels. In a single-arm inter-patient dose escalation phase I clinical protocol, bolus infusions of DT388IL3 will be given to patients with relapsed or refractory AML.
Specific Aim 4 will estimate the preliminary response rate and correlate it with drug and antibody levels, patients leukemic blast IL3 receptor content, and patient leukemic progenitor sensitivity in vitro. These studies will hopefully lead to the design of pivotal phase II and III clinical trials which will define the role of DT388IL3 in the management of AML.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA090263-02
Application #
6622624
Study Section
Special Emphasis Panel (ZRG1-CONC (01))
Program Officer
Wu, Roy S
Project Start
2002-03-13
Project End
2007-02-28
Budget Start
2003-03-01
Budget End
2004-02-29
Support Year
2
Fiscal Year
2003
Total Cost
$256,320
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Hall, Philip D; Beagle, Kathryn L; Garrett-Mayer, Elizabeth et al. (2008) Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. Anticancer Drugs 19:1007-11
Frankel, Arthur; Liu, Jen-Sing; Rizzieri, David et al. (2008) Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma 49:543-53
Watson, Linley E; Mock, Jonathan; Lal, Hind et al. (2007) Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction. Front Biosci 12:4670-5
Thorburn, Andrew; Frankel, Arthur E (2006) Apoptosis and anthracycline cardiotoxicity. Mol Cancer Ther 5:197-9
Hogge, Donna E; Yalcintepe, Leman; Wong, Siaw-Hui et al. (2006) Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res 12:1284-91
Liu, Tie Fu; Hall, Philip D; Cohen, Kimberley A et al. (2005) Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 11:329-34
Testa, Ugo; Riccioni, Roberta; Biffoni, Mauro et al. (2005) Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood 106:2527-9
Urieto, Jeffrey O; Liu, TieFu; Black, Jennifer H et al. (2004) Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif 33:123-33
Westcott, Marlena M; Abi-Habib, Ralph J; Cohen, Kimberley A et al. (2004) Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. Mol Cancer Ther 3:1681-9
Cohen, Kimberley A; Liu, Tie Fu; Cline, J Mark et al. (2004) Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leuk Lymphoma 45:1647-56

Showing the most recent 10 out of 17 publications